Immune Design Corp. (NASDAQ:IMDZ)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Group LLC in a note issued to investors on Wednesday, June 28th. They presently have a $18.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 56.52% from the company’s current price.
A number of other equities research analysts have also issued reports on IMDZ. Zacks Investment Research raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Thursday, May 18th. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th.
Shares of Immune Design Corp. (IMDZ) traded down 3.77% during mid-day trading on Wednesday, reaching $11.50. The company’s stock had a trading volume of 172,252 shares. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05. The firm’s market cap is $294.07 million. The company’s 50-day moving average is $9.18 and its 200 day moving average is $6.92.
In other news, Director Lewis W. Coleman bought 10,000 shares of the firm’s stock in a transaction dated Monday, July 10th. The stock was acquired at an average price of $9.00 per share, for a total transaction of $90,000.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $360,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Lewis W. Coleman purchased 12,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average price of $9.05 per share, with a total value of $108,600.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at $362,000. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 30,000 shares of company stock worth $272,760. 42.90% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in IMDZ. Bank of America Corp DE boosted its position in Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares during the period. Trexquant Investment LP acquired a new position in Immune Design Corp. during the first quarter valued at approximately $183,000. TIAA CREF Investment Management LLC boosted its position in Immune Design Corp. by 18.9% in the first quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 7,236 shares during the period. Personal Capital Advisors Corp purchased a new stake in Immune Design Corp. during the second quarter valued at about $356,000. Finally, Renaissance Technologies LLC raised its stake in Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after buying an additional 70,351 shares in the last quarter. Institutional investors own 50.47% of the company’s stock.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.